Over the past 10 years, biomarkers have made a significant impact on the oncology therapeutic landscape, but there is still room for improvement to appropriately identify the right patient for the right treatment. Research trends have begun to shift to look at proteomics for a more comprehensive view of the patient’s dynamic disease state and an understanding of their immune profile and immune response to cancer.

Join Biodesix for a webinar demonstrating how artificial intelligence is being coupled with mass spectrometry to extract important protein-based biological information from blood samples for biomarker discovery and diagnostic test development.